2-Bromoimidazo[2,1-b]thiazole-6-carboxylic acid, 95.0%, 500mg

3-Chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one, 95.0%, 100g

5-((Tert-butoxycarbonyl)amino)-2-methylthiazole-4-carboxylic acid, 97%, 250mg

JZL 184>95.0%(HPLC)(qNMR)25mg

Boc-Ala-NH2, 95%, 100g

2-(N,N-DiBoc-amino)-5-bromopyridine, 95.0%, 1g

11-((tert-Butoxycarbonyl)amino)undecanoic acid, 95.0%, 100g

(3R,5R)-3,5-Dimethylmorpholine hydrochloride, 95.0%, 5g

E-Plan phase EPLPH 10x/0.25 objective. Working distance 6.61 mm

Methyl 6-bromopyridazine-3-carboxylate, 95.0%, 250mg

(5,6-Dichloro-1H-benzo[d]imidazol-2-yl)methanamine hydrochloride, 98%, 100mg

2-Fluorobenzene-1,4-diamine, 95%, 25g

tert-Butyl 4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, 95.0%, 250mg